Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib and Chidamide in Newly Diagnosed PTCL
NCT05976997Phase 2Recruiting
- Start
- May 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of duvelisib, tucidinostat in peripheral T-cell lymphoma (PTCL). Started May 2023; status: recruiting.
02
Drugs
duvelisibtucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05976997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05976997.